Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seralutinib in Pulmonary Arterial Hypertension
NCT05934526Phase 3Completed
- Sponsor
- GB002, Inc.
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of seralutinib in pulmonary arterial hypertension (PAH), sponsored by GB002, Inc.. Started Dec 2023; status: completed.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05934526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934526.